dermatology

News

Almirall CEO Carlos Gallardo and Alberto Granados, president of Microsoft Spain

Almirall, Microsoft team up on digital dermatology drive

Almirall has taken another step forwards in the development of a digital approach to managing and treating dermatological conditions, forming a three-year alliance with Mi

News

LEO says chronic hand eczema drug bests its only rival

Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther

News

Sun Pharma reaches deal to buy out Taro in $347m deal

India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.

News

MHRA imposes restrictions on acne drug in children

The UK medicines regulator has tightened up controls on the prescription of acne treatment isotretinoin to patients under the age of 18, following a review prompted by con

News

Almirall signs $210m bispecifics deal with EpimAb

A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner

News

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the

Almirall, Microsoft team up on digital dermatology drive

LEO says chronic hand eczema drug bests its only rival

Sun Pharma reaches deal to buy out Taro in $347m deal

MHRA imposes restrictions on acne drug in children

Almirall signs $210m bispecifics deal with EpimAb

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

dermatology

Editor's Picks